| Wang |
NCT04938700: Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children |
|
|
| Recruiting | 4 | 200 | RoW | probiotics, conventional medical treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Hospital of TCM, The Children's Hospital of Zhejiang University School of Medicine, The First Affiliated Hospital with Nanjing Medical University, Zibo Central Hospital, First People's Hospital Affiliated to Huzhou University | Rhinitis, Allergic, Asthma, Dermatitis, Atopic, Urticaria | 03/23 | 12/23 | | |
| Recruiting | 3 | 41 | Europe, Canada, Japan, US, RoW | Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO) | Swedish Orphan Biovitrum | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 09/24 | 09/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT05188859: First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma |
|
|
| Not yet recruiting | 2 | 29 | RoW | Sintilimab+Anlotinib+Pemetrexed+Cisplatin, S+A+PC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced | 07/24 | 01/26 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
NCT03658785: Immunotherapy for the Treatment of Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 40 | RoW | TIL, Aldesleukin, IL-2, Cyclophosphamide, CTX, Fludarabine | Tongji Hospital | Recurrence Tumor, Metastatic Cancer, Solid Tumor | 12/24 | 12/25 | | |
NCT06239623: ERK Inhibitor JSI-1187 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | JSI-1187 | JS InnoPharm, LLC | Solid Tumor, NSCLC, Melanoma | 09/24 | 12/24 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
MLD, NCT05596929: Build-up Computed Assisted History Taking, Physical Examination and Diagnosis System of Emergency Patient Through Machine Learning (II) |
|
|
| Recruiting | N/A | 3000 | RoW | Artificial intelligence | National Taiwan University Hospital | Internal Disease | 03/23 | 03/23 | | |
NCT05904340: Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated With Chemotherapy Induced Peripheral Neuropathy |
|
|
| Not yet recruiting | N/A | 86 | RoW | Transcutaneous Electrical Nerve Stimulation, Transcutaneous Electrical Acupoint Stimulation | National Taipei University of Nursing and Health Sciences, Changhua Christian Hospital | Breast Neoplasms, Chemotherapy-induced Peripheral Neuropathy | 10/23 | 04/24 | | |
NCT06198894: Steroid-eluting Sinus Stent for Chronic Rhinosinusitis Patients With Uncontrolled Postoperative Symptoms |
|
|
| Recruiting | N/A | 96 | RoW | steroid-eluting sinus stent implant, BISORB bioabsorbable steroid-eluting sinus stent, Systemic glucocorticoids, Medrol, saline irrigations, 0.9% sodium chloride solution, Placebo, Systemic glucocorticoid placebo, sham procedure, In-office bilateral sham procedure of stent placement | Zheng Liu | Chronic Sinusitis | 01/26 | 04/26 | | |
| Tanczer |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
